Anteris Technologies Global Corp. (AVR) AI Stock Analysis

• Market Cap: $210.52M
• Dividend Yield: N/A
• Average Volume (3M): 151.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.07
• Revenue Growth: -21.10%
• EPS Growth: -18.32%
• Country: US
• Employees: 136
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.62
• Shares Outstanding: 41,197,570
• 10 Day Avg. Volume: 215,658
• 30 Day Avg. Volume: 151,395
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.80
• Price to Sales (P/S): 41.81
• P/FCF Ratio: -1.78
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: 72.54
• Enterprise Value/Gross Profit: 106.77
• Enterprise Value/Ebitda: -1.83
• 1Y Price Target: $19.00
• Price Target Upside: 271.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $5.00 ▼(-2.15% Downside)

The score is held down primarily by weak financial performance (declining revenue, large losses, and negative cash flow). Offsetting this are constructive technical trend signals and meaningful positive corporate milestones (FDA-approved pivotal trial progress and positive clinical outcomes), while valuation remains unattractive due to ongoing losses and no dividend support.

Positive Factors

FDA approval for PARADIGM pivotal trial

Securing FDA approval to start a global pivotal trial materially advances regulatory de-risking for DurAVR. A roughly 1,000-patient comparative study across US, Europe and Canada creates a clear pathway to PMA/CE, supporting long-term commercialization and market access if results remain favorable.

Favorable early DurAVR clinical outcomes

Positive 30-day data in 100 patients demonstrating no valve-related mortality and improved hemodynamics strengthens clinical credibility. Durable clinical differentiation versus existing TAVRs can drive clinician adoption, reimbursement prospects, and competitive positioning during regulatory review and commercialization.

Conservative leverage

Very low debt-to-equity provides financial flexibility to fund ongoing pivotal trials and commercialization investments without high fixed interest burdens. Conservative leverage reduces bankruptcy risk and preserves capacity to raise project finance or absorb trial-related working capital needs during a multi-year product approval cycle.

Negative Factors

Declining revenue and sustained losses

Material revenue contraction and deeply negative margins indicate the business has not yet translated clinical progress into sustainable sales. Persistent losses reduce internal funding capacity and lengthen the time to break-even, increasing reliance on external capital and putting long-term shareholder returns at risk if commercialization stalls.

Negative operating and free cash flow

Continued negative operating and free cash flow signal structural cash burn from R&D and commercialization buildouts. This weak cash generation undermines reinvestment ability, forces financing that may dilute equity, and makes the company vulnerable to funding market cycles during the multi-year regulatory and commercialization timeline.

Ongoing reliance on equity financings

Large shelf filing and prior equity raises indicate a repeat dependence on external capital to fund operations and trials. Recurrent dilution risk can erode shareholder value and signals the company lacks self-sufficient cash generation, complicating long-term returns unless product approvals and commercial revenues accelerate materially.

Anteris Technologies Global Corp. Business Overview & Revenue Model

Company Description

Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.

How the Company Makes Money

Anteris Technologies generates revenue primarily through the commercialization of its medical devices and therapeutic products. The company's revenue model includes direct sales of its products to healthcare providers and institutions, as well as potential licensing agreements for its proprietary technologies. Strategic partnerships with healthcare organizations and research institutions also play a significant role in its earnings, enabling Anteris to expand its market reach and drive innovation. Additionally, the company may benefit from government grants and funding aimed at supporting medical research and development, which could further contribute to its financial growth.

Anteris Technologies Global Corp. Financial Statement Overview

Summary

Anteris Technologies faces significant financial challenges with declining revenue, negative profitability, and cash flow issues. Despite a high gross profit margin and low leverage, the negative return on equity and cash flow deficits highlight the need for strategic improvements.

Income Statement

Anteris Technologies Global Corp. has experienced declining revenue with a negative growth rate of -13.71% in TTM. The company shows a negative net profit margin of -33.97% and EBIT margin of -26.25%, indicating significant losses. Despite a relatively high gross profit margin of 59.41% in TTM, the overall profitability is weak due to high operating expenses and negative net income.

Balance Sheet

The company's debt-to-equity ratio is low at 0.115, suggesting conservative leverage. However, the return on equity is negative at -252.22%, reflecting poor profitability and returns for shareholders. The equity ratio stands at 19.39%, indicating a moderate level of equity financing relative to total assets.

Cash Flow

Anteris Technologies has a negative operating cash flow and free cash flow, with a slight improvement in free cash flow growth of 4.50% in TTM. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is marginally better than net income, but still negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.14M	2.70M	2.73M	3.20M	5.83M	5.46M
Gross Profit	1.45M	1.27M	876.80K	298.38K	1.91M	3.36M
EBITDA	-84.73M	-76.86M	-45.54M	-29.14M	-15.50M	-14.05M
Net Income	-84.32M	-76.29M	-46.02M	-30.56M	-17.17M	-11.78M
Balance Sheet
Total Assets	19.07M	80.70M	30.53M	15.99M	21.43M	9.75M
Cash, Cash Equivalents and Short-Term Investments	9.12M	70.46M	21.03M	9.29M	15.46M	3.36M
Total Debt	2.35M	1.40M	1.60M	952.79K	4.14M	2.92M
Total Liabilities	15.71M	18.02M	11.63M	6.95M	10.91M	7.90M
Stockholders Equity	3.70M	62.76M	19.30M	9.03M	10.52M	1.86M
Cash Flow
Free Cash Flow	-79.43M	-63.51M	-37.03M	-31.08M	-15.02M	-11.30M
Operating Cash Flow	-77.51M	-61.24M	-34.63M	-29.42M	-14.44M	-11.08M
Investing Cash Flow	-562.57K	-2.28M	-2.58M	-992.57K	-886.07K	5.99M
Financing Cash Flow	76.57M	112.83M	49.34M	23.27M	27.42M	1.46M

Anteris Technologies Global Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVR, the sentiment is Positive. The current price of 5.11 is above the 20-day moving average (MA) of 4.98, above the 50-day MA of 4.51, and above the 200-day MA of 4.23, indicating a bullish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 56.65 is Neutral, neither overbought nor oversold. The STOCH value of 50.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVR.

Anteris Technologies Global Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APYX	60 Neutral	$163.71M	-10.95	-172.18%	―	-1.32%	55.62%
RPID	56 Neutral	$185.27M	-4.19	-68.83%	―	16.63%	10.43%
AVR	52 Neutral	$210.52M	-2.18	-2462.70%	―	-21.10%	-18.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANIK	50 Neutral	$134.26M	-4.09	-8.73%	―	-31.29%	65.68%
INGN	50 Neutral	$169.68M	-6.23	-13.27%	―	4.68%	55.37%
TMCI	45 Neutral	$168.22M	-3.32	-51.63%	―	7.90%	19.92%

Anteris Technologies Global Corp. Corporate Events

Stephen Denaro Resigns from Anteris Board

On December 13, 2025, Stephen Denaro resigned from the Board of Directors of Anteris Technologies Global Corp. and as a Class II director, effective immediately. His resignation was not due to any disagreements with the company, and he will continue to serve as the corporate secretary of Anteris Technologies Pty Ltd and as a member of the Board of Directors of the company’s Australian subsidiaries.

The most recent analyst rating on (AVR) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Holds Annual Stockholders Meeting

On December 3, 2025, Anteris Technologies Global Corp. conducted its Annual Meeting of stockholders, where several key proposals were voted on. These included the election of John Seaberg and Gregory Moss as directors, the appointment of KPMG as the independent auditor for 2025, and the approval of various grants of restricted stock units (RSUs) to key executives in connection with the company’s U.S. initial public offering and annual meeting. Additionally, amendments to the company’s Employee Incentive Plan and previous incentive plans were approved, reflecting strategic adjustments to enhance executive compensation and corporate governance.

The most recent analyst rating on (AVR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Ends Agreement with 4C Medical

On November 26, 2025, Anteris Technologies Global Corp. announced it would not renew its Supply and License Agreement with 4C Medical Technologies, Inc., which involved the supply of ADAPT® tissue for medical devices. This decision, effective June 1, 2026, will not incur early termination penalties and does not materially impact the company’s financial results.

The most recent analyst rating on (AVR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Reports Positive DurAVR® THV Outcomes

On November 16, 2025, Anteris Technologies Global Corp. announced the 30-day clinical outcomes for its DurAVR® Transcatheter Heart Valve (THV) in 100 patients with severe aortic stenosis and small aortic annuli. The results, presented at the PCR London Valves conference, highlighted the valve’s favorable hemodynamic profile, with no valve-related mortality and a significant reduction in prosthesis-patient mismatch compared to existing commercial devices. These outcomes reinforce the potential of DurAVR® THV in advancing towards commercialization, with implications for improved patient outcomes in the treatment of aortic stenosis.

The most recent analyst rating on (AVR) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Receives FDA Approval for PARADIGM Trial

On November 3, 2025, Anteris Technologies Global Corp. announced that it received FDA approval to commence its PARADIGM Trial, a global pivotal study of the DurAVR® Transcatheter Heart Valve (THV). This trial, which has already begun in Denmark, marks a significant milestone for the company as it aims to provide robust clinical evidence to support a future Premarket Approval (PMA) submission in the United States and CE Mark approval in Europe. The trial will enroll approximately 1000 patients across the United States, Europe, and Canada to evaluate the safety and effectiveness of the DurAVR® THV compared to commercially available transcatheter aortic valve replacements (TAVRs).

The most recent analyst rating on (AVR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Begins Global PARADIGM Trial Enrollment

On October 27, 2025, Anteris Technologies announced the successful enrollment and treatment of the first patients in the global pivotal PARADIGM Trial for the DurAVR® Transcatheter Heart Valve (THV), aimed at patients with severe calcific aortic stenosis. This trial, which is expected to expand across the United States, Europe, and Canada, will provide comparative evidence on the safety and effectiveness of the DurAVR® THV against commercially available transcatheter aortic valve replacements, potentially impacting the company’s market positioning and treatment options for aortic stenosis patients.

The most recent analyst rating on (AVR) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Raises $11.5M in Stock Offering

On October 23, 2025, Anteris Technologies Global Corp. entered into agreements to sell shares of its common stock and CHESS Depositary Interests (CDIs), along with accompanying five-year warrants, to certain investors. The company successfully closed the offering on October 27, 2025, issuing 2,346,936 shares and warrants, and raising approximately US$11.5 million in gross proceeds.

The most recent analyst rating on (AVR) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Anteris Technologies Announces Share Sale Agreement

On October 23, 2025, Anteris Technologies Global Corp. announced agreements to sell over 5 million shares and accompanying warrants, expected to generate approximately US$25 million in gross proceeds. The offerings, managed by Evolution Capital Pty Ltd, are set to close by the end of October 2025, with the funds likely enhancing Anteris’ market position and supporting its strategic initiatives in the TAVR market.

The most recent analyst rating on (AVR) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.